Sleep problems, fatigue, and thinking ability in people with MS
Official title: The Effects of Sleep Disturbances on Fatigue and Cognition in Multiple Sclerosis
Run by Heinrich-Heine University, Duesseldorf · NCT07426991 · Data updated 2026-11-12
We will try to see if sleep problems explain why adults with MS feel very tired and have trouble thinking.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 79 Years |
| Sex | All |
| Enrollment | 837 (estimated) |
| Sponsor | Heinrich-Heine University, Duesseldorf Academic / other |
| Drugs / interventions | immunotherapy, Ocrelizumab |
| Locations | 2 sites (Düsseldorf and 1 other locations) |
| Status | Recruiting |
| Started | November 1, 2024 |
| Main results expected | January 2028 |
| Study ends | December 2028 |
| Registry record updated | March 6, 2026 |
| Trial ID | NCT07426991 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–79 with a diagnosis of MS (2017 McDonald criteria), at least mild fatigue (FSMC ≥ 43), adequate hearing/vision, German language proficiency, and capacity to consent are ideal candidates.
✕Probably not a fit
People outside the 18–79 age range, those with other neurological disorders (except migraine), or those taking medications that alter sleep recordings may not benefit from the study findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort enrolls adults with multiple sclerosis who have at least mild fatigue and compares them with control participants referred for sleep evaluation. Participants undergo overnight polysomnography, standardized questionnaires (including the FSMC), and objective motor and cognitive fatigability testing to link sleep architecture to subjective and objective fatigue and cognitive performance. The study will compare patients with and without sleep-related abnormalities and explore which sleep parameters most strongly correlate with fatigue severity and performance decline. Standard eligibility criteria (age 18–79, German language proficiency, adequate hearing/vision, and no interfering medications or other neurological disorders) are applied.
Why it matters
Potential benefit: If successful, the findings could identify treatable sleep disorders that, when addressed, reduce fatigue and improve thinking and quality of life for people with MS.
How similar studies have gone: Prior research has linked sleep disorders to fatigue and cognitive problems in MS, but few studies used full polysomnography and causal relationships remain unproven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 and ≤ 79 years (all groups) * Adequate (corrected) hearing and vision to complete neuropsychological testing (all groups) * Sufficient proficiency in German to participate in assessments (all groups) * Capacity to provide informed consent and understanding of study procedures (all groups) * Diagnosis of MS according to the 2017 revised McDonald criteria (MS group) * Indication for sleep medicine evaluation due to at least mild fatigue, operationalized as ≥ 43 points on the Fatigue Scale for Motor and Cognitive Functions (FSMC) (MS group) * Indication for sleep medicine evaluation (control group) Exclusion Criteria: * Lack of signed informed consent or inability to provide consent (all groups) * Age \< 18 years or \> 79 years (all groups) * Presence of another neurological disorder in addition to MS, with the exception of migraine (all groups) * Use of medications that influence polysomnographic parameters (e.g., benzodiazepines) (all groups) * Uncorrected hearing or vision impairment and/or insufficient German language proficiency likely to impact neuropsychological test results (all groups)
Where it's running
-
University Hospital Düsseldorf
Düsseldorf, Germany Recruiting -
Maria Hilf Clinics
Mönchengladbach, Germany Recruiting
Study contacts
- Study coordinator: Carolin Balloff, Dr. rer. nat.
- Email: carolin.balloff@gmail.com
- Phone: +4917622970340
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TRX319 treatment for people with primary or secondary progressive multiple sclerosis
This trial will test whether the experimental therapy TRX319, given with or without a short bendamustine pre-conditioning, is safe and can slow or improve disability in adults with primary or secondary progressive MS.
-
Treadmill-based virtual reality walking training for MS patients
This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.
-
Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS
This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.
-
REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care
This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.
-
Tolebrutinib in real-world MS care for patients treated by clinicians
This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.
-
Pilates via live video vs. prerecorded videos for people with multiple sclerosis
This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.